Artelo Biosciences announces publication of research on SBFI103

Artelo Biosciences (ARTL) announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, partially funded by the Company, demonstrating that intraperitoneal administration of Artelo’s proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like effects in a validated preclinical model of chronic stress. The paper, titled “Inhibition of fatty acid binding protein 5 prevents stress-induced anxiogenic and depressive-like symptoms through modulation of hippocampal neurogenesis, cannabinoid and neurotrophic signaling in the limbic circuitry,” was published in Neurobiology of Disease. Key Findings: The newly published study demonstrates that intraperitoneal administration of SBFI103 leads to significant: Reductions in anxiety- and depression-like behaviors in chronically stressed rats after a single dose, with no adverse impact on locomotion or memory; Increased gene expression of key receptors within the endocannabinoid system, including CB2, GPR55, and TRPV1, in the hippocampus; Prevention of stress-induced reductions in biomarkers associated with depression in the hippocampus; Blocking of the detrimental effects of chronic stress on hippocampal neurogenesis, a critical biological process linked to mood regulation and cognitive function